formestane
Sign in to saveAlso known as LTR323, CGP-32349, 4-hydroxy-Δ4-androstenedione, 4-hydroxy-4-androstene-3,17-dione, CGP 32349, Formestano, Formestanum, 4-hydroxyandrostenedione
Formestane, formerly sold under the brand name Lentaron among others, is a steroidal, selective aromatase inhibitor which is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and was available only as an intramuscular depot injection. Formestane was not approved by the United States FDA and the injectable form that was used in Europe in the past has been withdrawn from the market. Formestane is an analogue of androstenedione.
Research
415 papers- Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.Drugs · 1993
- Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.Drugs & aging · 1996
- Formestane for advanced breast cancer in postmenopausal women.Drug and therapeutics bulletin · 1993
- Metabolism of formestane in humans: Identification of urinary biomarkers for antidoping analysis.Steroids · 2019
- The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment.Frontiers in immunology · 2023
via PubMed
Wikidata facts
- Mass
- 302.188195
Show 6 more facts
- chemical formula
- C₁₉H₂₆O₃
- canonical SMILES
- CC12CCC(=O)C(=C1CCC3C2CCC4(C3CCC4=O)C)O
- isomeric SMILES
- C[C@]12CCC(=O)C(=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
- World Health Organisation international non-proprietary name
- formestane
- defined daily dose
- 18
- Commons category
- Formestane
via Wikidata · CC0
~1 min read
Article
3 sectionsContents
- Chemistry
- Synthesis
- References
Formestane, formerly sold under the brand name Lentaron among others, is a steroidal, selective aromatase inhibitor which is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and was available only as an intramuscular depot injection. Formestane was not approved by the United States FDA and the injectable form that was used in Europe in the past has been withdrawn from the market. Formestane is an analogue of androstenedione.
Formestane is often used to suppress the production of estrogens from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a weak aromatase inhibitor.